Topix Pharmaceuticals, Inc. has partnered with New Mountain Capital, LLC, a growth-oriented investment firm that currently manages over $15 billion in assets. New Mountain, a New York-based private equity firm, identified Topix through a proactive focus in the life sciences and aesthetics industries.  New Mountain is providing Topix with significant financial and strategic resources to support future growth initiatives which include new product development and acquisitions.

Topix’s product portfolio addresses a wide array of skin health conditions and includes leading brands Replenix^TM, Citrix^TM, Glycolix^TM, and ReBrightalyze^TM as well as customized, private label solutions for the professionally dispensed market.  Topix utilizes its own state-of-the-art, GMP-compliant facilities to research, develop, manufacture and test its products to the highest quality standards.

“Topix is the high quality leader in its space, and we are excited to partner with the Topix team to support the next phase of growth,” said Andre Moura, Managing Director at New Mountain Capital.  “We look forward to working closely with management to help the Company realize its full growth potential by investing in new products, new channel strategies, new technologies and acquisitions, while maintaining the high level of quality and customer service which have always been the hallmarks of Topix’s success.”

“New Mountain is the perfect partner to help Topix execute on its growth plans,” said Burt Shaffer, President and CEO of Topix.  “New Mountain is known for its focus on business building, and Topix will have deep resources at its disposal to help us achieve our strategic growth objectives.  We look forward to our partnership and the benefits it will yield for our customers and employees.”